## RESEARCH



# Medium and long-term radiographic and clinical outcomes of Dynesys dynamic stabilization versus instrumented fusion for degenerative lumbar spine diseases



Lu-Ping Zhou<sup>1+</sup>, Ren-Jie Zhang<sup>1+</sup>, Jia-Qi Wang<sup>1</sup>, Hua-Qing Zhang<sup>1</sup>, Jin Shang<sup>2</sup>, Yang Gao<sup>3</sup>, Chong-Yu Jia<sup>1</sup>, Jing-Yu Ding<sup>1</sup>, Lai Zhang<sup>1</sup> and Cai-Liang Shen<sup>1\*</sup>

## Abstract

**Background** Dynesys stabilization (DS) is utilized to preserve mobility at the instrumental segments and prevent adjacent segment pathology in clinical practice. However, the advantages of DS method in medium and long-term follow-up remain controversial.

**Objective** To compare the radiographic and clinical outcomes between DS and instrumented fusion in the treatment of degenerative lumbar spine disease with or without grade I spondylolisthesis with a minimum follow-up period of 2 years.

**Methods** We conducted a comprehensive search of PubMed, EMBASE, Cochrane, and Web of Science databases, Chinese National Knowledge Databases, and Wanfang Database for potentially eligible articles. Clinical outcomes were assessed in terms of VAS and ODI scores, screw loosening and breakage, and surgical revision. Radiographic outcomes were assessed in terms of postoperative range of movement (ROM) and disc heigh. Moreover, adjacent segment degeneration (ASDeg) and adjacent segment disease (ASDis) were evaluated.

**Results** Seventeen studies with 1296 patients were included in the meta-analysis. The DS group was associated with significantly lower postoperative VAS scores for low-back and leg pain, and lower rate of surgical revision than the fusion group. Moreover, the Dynesys group showed significantly less ASDeg than the fusion group but showed no significant advantage over the fusion group in terms of preventing ASDis. Additionally, the ROM at the stabilized segments of the fusion group decreased significantly and that at the adjacent segments increased significantly compared with those of the DS group.

**Conclusion** DS showed comparable clinical outcomes and provided benefits in preserving the motion at the stabilized segments, thus limiting the hypermobility at the adjacent segments and preventing ASDeg compared with the fusion method in degenerative disease with or without grade I spondylolisthesis.

Keywords Dynamic stabilization, Dynesys, Fusion, Lumbar, Pedicle screw

 $^{\dagger}\mbox{Lu-Ping}$  Zhou and Ren-Jie Zhang contributed equally to the work and should be regarded as co-first authors.

\*Correspondence: Cai-Liang Shen shencailiang@ahmu.edu.cn Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

Lumbar fusion has been considered as the gold standard for the treatment of lumbar degenerative pathologies over the last decades [1, 2]. However, instrumented fusion causes a series of complications, including instrumentation failure, pseudoarthrosis, and pain in donors [3–5]. Moreover, the preservation of lumbar motion is less considered in fusion instrument, thus limiting the motility of stabilized segments and the increased load on adjacent segment, which may increase the risk of adjacent segment degeneration (ASDeg), adjacent segment disease (ASDis), and severe post-operative functional disabilities [6–8].

In recent years, non-fusion systems have been applied clinically to prevent the incidence of adjacent segment pathology (ASP, including ASDeg and ASDis) after lumbar surgeries [9–11]. The Dynesys posterior dynamic stabilization system (Zimmer Inc., Warsaw, IN, USA), which was first introduced in 1994, is a commonly used dynamic stabilization device [12]. This system consists of pedicle screws (Ti alloy), polyethylene-terephtalate (PET) cords, and polycarbonate-urethane (PCU) spacers for the stabilization of stabilized segments, restoration of normal segmental kinematics, and preservation of adjacent motion, and these parts aim to prevent the instability and decrease ASP incidence [5, 13, 14]. The Dynesys system (DS) has shown significant improvement in terms of visual analog scale (VAS) pain scores, Oswestry disability index (ODI) scores, trauma severity, and recovery time compared with the fusion method [4, 15-18]. Moreover, the range of movement (ROM) at adjacent segments and along with the load across the intervertebral and adjacent discs has been reduced [4, 7, 13, 15, 19].

However, inconsistent results have been obtained in the advantages of DS over fusion method in terms of clinical outcomes, including the relief in post-operative pain status (VAS scores) and functional status restoration (ODI scores) [3, 5–7, 20–23]. Whether DS can retain ROM at surgical segment and reduce ASP in long-term follow-up remains controversial [5, 6, 23]. Furthermore, previous studies have mainly focused on short-term clinical efficiency, and limited reports have focused on medium and long-term outcomes with conflicting findings, especially trials involving fusion method as control [7, 15, 24-26]. Thus, this metaanalysis aimed to compare the radiographic and clinical outcomes of dynamic DS and instrumented fusion for the treatment of degenerative lumbar spine diseases with a minimum follow-up period of 2 years.

## Methods

## Search strategy

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Metaanalyses guidelines [27]. A systematic search on PubMed, EMBASE, Cochrane, Web of Science databases, Chinese National Knowledge Databases, and Wanfang Database was conducted to identify potentially eligible articles from inception up until November 14, 2022 without language restriction. The terms "Dynesys" or "dynamic" or "semi-rigid" and "fusion" and "lumbar" were used for the search. The detailed search strategy is summarized in Additional file 1. Two reviewers independently searched all the titles and abstracts. The reference lists of relevant studies on DS were also reviewed for additional literature. Full-text articles were obtained when uncertainties were encountered. Any disagreement was settled by a third reviewer.

## Inclusion and exclusion criteria

The inclusion and exclusion of studies for the metaanalysis were based on the following criteria. (1) For participants, the study population consisted of patients who satisfied the following criteria: aged 18 years or older; mean follow-up period  $\geq 2$  years; suffering from lumbar degenerative diseases, including disc herniation, lumbar spinal stenosis, and grade I degenerative spondylolisthesis; and having 1-4 fixed segments in the lumbar. Studies on patients with grade II or higher spondylolisthesis, ankylosis spondylitis, spinal tumor, and severe spinal deformity were excluded. (2) The intervention in the experimental group was dynamic DS. Studies on hybrid dynamic stabilization and other kinds of dynamic stabilization, including Coflex, Wallis, and X-stop systems were excluded. (3) For comparison, the intervention in the control group was instrumented fusion methods, including posterior lumbar interbody fusion, transforaminal lumbar interbody fusion (TLIF), and posterolateral fusion. (4) In terms of outcomes, studies were eligible if they satisfied at least one of the following outcomes: clinical outcomes at final follow-up (VAS and ODI scores, screw loosening and breakage, surgical revision), ASP (ASDeg and ASDis), and radiographical outcomes (postoperative ROM and disc heigh). ASDeg (radiographic ASD) represents radiographic etiologies adjacent to the surgically treated spinal level that involves loss of disc height, disc degeneration, stenosis, instability, or hypertrophic facet arthritis, regardless of the presence of symptoms. [8] ASDis (symptomatic ASD) is a clinical symptom (manifested as pain, numbness, or the other symptoms caused by nerve compression) that is correlated with radiographic changes in adjacent segments. [2, 8] The primary outcomes considered were radiographic outcomes and ASP. (5) For study design, randomized controlled trials (RCTs) or comparative studies were eligible. Case series, case reports, reviews, and conference reports were excluded.

## **Risk of bias assessment**

Cochrane risk-of-bias criteria [28] and Newcastle-Ottawa Scale (NOS) [29] were used to assess the methodological quality of the included RCTs and comparative studies. The included randomized controlled trials were evaluated based on randomization sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. We defined other biases as different baseline characteristics in the experimental and control groups. The bias of domains was qualified as low risk, high risk, or unclear risk. Meanwhile, comparative cohort studies were assessed in terms of selection of patients, comparability, and outcomes of the case and control groups, with scores ranging from 0 to 9. The studies were evaluated as high quality (score 8 or 9), moderate quality (score 6 or 7), and low quality (score 5 or less).

## **Data extraction**

Two reviewers independently extracted relevant data from the qualified studies. Any disagreement was settled by a third reviewer. Leading author, publication year, study design, country of origin, study period, age, gender distribution, number of treated segments, fusion type, and follow-up period were extracted from the included studies.

## Statistical analysis

Odds ratio (OR) and its 95% confidence interval (CI) were calculated for dichotomous data. Mean difference (MD) and its 95% CI were calculated for continuous data. We used  $I^2$  and chi-squared tests at a significance level of P < 0.05 for assessment of statistical heterogeneity. A fixed-effects model was utilized if no evidence of heterogeneity ( $I^2 < 50\%$ ) was observed among the studies. Otherwise, a random-effects model was used. The sensitivity analyses were performed to investigate the source of heterogeneity. In addition, publication bias was evaluated by Egger tests when the number of included studies was 9 or more. Except for publication bias assessed by STATA version 15.1, statistical analysis was performed with Review Manager version 5.3. All tests were two-tailed, and P < 0.05 was considered statistically significant.

## Results

## Study search

The process for literature search is summarized in Fig. 1. A total of 3359 potential papers were inspected from the electronic searches, and 1171 studies were excluded because of duplication. After assessing the titles and abstracts, 2127 studies were removed, and the 61 remaining articles were downloaded for full-text verification. Finally, one prospective randomized controlled trial [21], five prospective clinical studies [3, 15–17, 30], and 11 retrospective studies [4, 7, 22, 24–26, 31–35] were deemed eligible and included in the meta-analysis.

## Main characteristics of the included studies

Table 1 summarizes the main characteristics of the included studies. The baseline information of the 17 studies was balanced and comparable. Among the included studies, 14 studies [3, 4, 7, 15–17, 21, 22, 24, 30–34] were conducted in China, and one study was conducted in France [35], Italy [25], and the UK [26].

## Risk of bias in the included studies

The risk of bias for the included studies are shown in Additional file 2 and Additional file 3. The only randomized controlled trial [21] was of moderate quality and showed adequate randomization and allocation concealment. However, the blinding of participants and personnel and blinding of outcome assessment were of high risk. For the comparative cohort studies assessed by NOS, seven studies [3, 7, 15, 17, 24, 25, 31] were of sufficiently high quality, and nine studies [4, 16, 22, 26, 30, 32–35] were of moderate quality.

## Meta-analysis results Clinical outcomes at final follow-up Postoperative VAS scores

Four prospective studies [3, 15, 17, 30] provided data on post-operative back pain and leg pain scores between Dynesys and fusion groups. The combined results indicated that the postoperative VAS scores for low back pain (MD = -0.26, 95% CI of -0.34 to -0.17, P < 0.001, I<sup>2</sup> = 0%; Fig. 2A) and leg pain (MD = -0.28, 95% CI of -0.44 to -0.13, P < 0.001, I<sup>2</sup> = 0%; Fig. 2B) in the Dynesys group were better than those in the fusion group.

## Postoperative ODI scores

Four prospective studies [3, 15, 16, 30] provided data on post-operative ODI scores. The combined results revealed that the Dynesys group was insignificantly different from the fusion group in terms of postoperative



Fig. 1 Flow diagram of the study selection

ODI scores (MD = 0.66, 95% CI of - 0.75 to 2.06, P = 0.36,  $I^2 = 0\%$ ; Fig. 2C).

### Screw loosening and breakage

Eleven studies [7, 15, 17, 21, 22, 24, 26, 31–33, 35] and five studies [3, 4, 7, 33, 35] provided data on screw loosening and breakage, respectively. The pooled results showed that the Dynesys group was insignificantly different from the fusion group in terms of screw loosening (OR = 1.10, 95% CI 0.64–1.87, P=0.73; I<sup>2</sup>=0%; Fig. 3A) and screw breakage (OR=0.77, 95% CI 0.27–2.17, P=0.62; I<sup>2</sup>=15%; Fig. 3B). The Egger's test suggested no publication bias of screw loosening (coefficient = - 0.20, SE = 0.62, P=0.756).

## Surgical revision

Seven studies [3, 15, 21, 24, 26, 32, 33] provided surgical revision data. The pooled results indicated that the Dynesys group was associated with significantly lower rate of surgical revision than the fusion group (OR = 0.38, 95% CI 0.16–0.90, P=0.03; I<sup>2</sup>=0%; Fig. 3C).

## ASP (adjacent segment pathology) ASDeg (radiographic ASD)

Eight studies [15, 22, 24, 25, 32–35] provided ASDeg data. The pooled results indicated that the Dynesys group showed less ASDeg than the fusion group (OR=0.24, 95% CI 0.15–0.39, P<0.001; I<sup>2</sup>=0%; Fig. 4A).

Study	Study design	Country	Study Period	Age (years)		Sex (M/F)		No. of	Type of fusion	Follow-up(months)	
				Dynesys	Fusion	Dynesys	Fusion	treated segments		Dynesys	Fusion
Luo et al., 2022	Retro	China, Chongqing	2013-2017	62.8±11.6	58.2 土 12.2	11/23	9/22	NA	TLIF	44 (36—78)	39 (30—73)
Zheng et al., 2021	Retro	China, Beijing	2012-2017	67.67 ± 5.70	66.98 土 6.11	16/24	15/24	2–3	PLIF	41.90土9.89	43.68 土 13.82
Zhang et al., 2021	Retro	China, Zhejiang	2010-2012	55.1 土 14.6	52.6土 16.8	14/9	12/8	2	PLIF	78.0 ± 25.6 (60-120)	
Hu et al., 2019	Retro	China, Shanghai	2011-2013	69.27 ± 4.92	69.41 土 4.23	11/11	22/22	1-3	TLIF	68.50 土 6.40	70.14土7.26
Ren et al., 2018	Retro	China, Sichuan	2011-2015	49.5 土 11.6	52.7 土 12.4	27/11	31/13	-	TLIF	25.4 土 4.0	24.8 土 5.2
Kuo et al., 2018	Retro	China, Taiwan	2007-2014	60.1 土 10.8	58.0±11.7	21/35	8/15	-	TLIF	35.2 (24–89)	
Wu et al., 2017	Pro	China, Zhejiang	2008-2010	49.6±8.3	52.5 ± 6.9	14/12	18/22	2-4	PLIF	50.3 (46—65)	52.8 (48 – 68)
Liu et al., 2017	Pro	China, Beijing	2011-2013	52.9±10.3	54.6 土 9.9	26/29	29/29	-	PLIF + TLIF	24	
Bredin et al., 2017	Retro	France, Marne	2005-2011	60.3 ± 9.4	61.3 土 8.4	18/15	13/12	1-2	PLF	93.6 土 16.5	91.7±13.5
Zhang et al., 2016	Retro	China, Beijing	2008-2011	48.1 土 12.3	52.3 土 12.9	31/15	37/13	1-3	PLIF	53.6±5.3	55.2 土 6.8
He et al., 2016	Pro	China, Jiangsu	NA	58.3 ± 13.5	61.4土15.2	7/5	9/15	1-2	PLIF	28.7 ± 5.3	30.1 土 6.8
Wang et al., 2016	Retro	China, Liaoning	2009–2013	42.8±6.7	56.8±6.2	24/21	17/23	2–3	PLIF	30.6±8.6	32.7 土 7.9
Fei et al., 2015	Pro	China, Jiangsu	2007-2009	47.3 土 12.9	52.9±11.2	51/44	40/41	1-3	PLIF	36–66	
Yang et al, 2014	Pro	China, Shanghai	2010-2012	55.96 ± 7.68	54.69±3.26	17/13	21/24	1-2	PLIF	26.64 ± 5.16	26.04 ± 9.12
Silvestre et al., 2014	Retro	Italy, Bologna	2002-2005	68.4 (61–78)	67.6 (62–77)	7/25	5/20	NA	PLIF	64 (42–90)	
Haddad et al., 2013	Retro	UK, London and Stanmore	2004–2006	40.6±6.46	46.5 土 10.7	19/13	15/17	NA	PLIF	48	
Yu et al., 2012	RCT	China, Taiwan	2006-2007	52.22 ± 8.31	55.52±6.98	10/17	11/18	-	PLIF	36	
RCT randomized contr posterolateral fusion, /	olled trial, <i>Pro</i> pro: VA not applicable	spective clinical trial, <i>Retro</i> retros	pective clinical tri	al, NOS Newcas	tle–Ottawa Scal	e, <i>TLIF</i> transf	oraminal lu	mbar interbody	y fusion, PLIF posteri	ior lumbar interbody fus	ion, <i>PLF</i>

usion,	
pody f	
' interl	
umbar	
erior	
F post	
on, PLI	
ly fusi	
terboc	
bar in	
al lum	
ramin	
transfc	
e, TLIF	
a Scale	
Ottaw	
castle-	
S Newo	
al, NO	
ical tri	
ve clini	
spectiv	
retro:	
l, Retrc	
cal tria	
e clinio	
pectiv	
o pros	cable
trial, <i>Pr</i>	t appli.
olled t	NA noi
d conti	usion,
mizec	teral fi
andc	rola

 Table 1
 Characteristics of included studies



Fig. 2 Forest plots of Dynesys stabilization versus instrumented fusion: (A) postoperative back VAS scores; (B) postoperative leg VAS scores; (C) postoperative ODI scores

## ASDis (symptomatic ASD)

Four studies [17, 24, 33, 35] provided ASDis data. The pooled results showed that the Dynesys group was insignificantly different from the fusion group in terms of ASDis (OR=0.39, 95% CI 0.11–1.40, P=0.15;  $I^2=0\%$ ; Fig. 4B).

## Radiographic outcomes Postoperative ROM

Five studies [3, 17, 22, 31, 35] provided data on postoperative ROM at stabilized segments. The pooled data indicated that the ROM at the stabilized segment in the fusion group decreased significantly than that in the Dynesys group (MD=3.87, 95% CI of 2.50 to 5.24, P < 0.001,  $I^2 = 98\%$ ; Fig. 5A). Sensitivity analysis was performed by sequential removal of the included trials due to the remarkable heterogeneity ( $I^2 = 98\%$ ). The results showed the same conclusion (MD=3.15, 95% CI of 2.86 to 3.43, P < 0.001,  $I^2 = 0\%$ ) as before.

Seven studies [4, 7, 15, 17, 24, 32, 33] provided data on post-operative ROM at proximal adjacent segment. The combined results indicated that the ROM in the fusion group increased significantly than that in the Dynesys group (MD=-2.08, 95% CI of -2.99 to -1.17, P < 0.001,  $I^2 = 95\%$ ; Fig. 5B). Sensitivity analysis was performed because of remarkable heterogeneity ( $I^2 = 95\%$ ). The obtained result (MD = -2.64, 95% CI of -3.15 to -2.12, P < 0.001,  $I^2 = 0\%$ ) was consistent with the above outcomes after removing the studies of Yang et al. [17] and Wang et al. [4] that caused heterogeneity.

Three studies [3, 31, 35] provided data on the postoperative ROM of L1–S1 lumbar lordosis (LL) angle. The combined results indicated that the ROM in the fusion group decreased significantly than that in the Dynesys group (MD=8.12, 95% CI of 0.42–15.81, P=0.040,  $I^2=99\%$ ; Fig. 5C). After the sensitivity analysis, the final result (MD=2.08, 95% CI of 1.33–2.83, P<0.001,  $I^2=0\%$ ) confirmed the above outcome.

## Postoperative disc height

Five studies [7, 15, 17, 24, 33] reported the disc height at the surgical segment, and four studies [7, 15, 24, 33] reported the disc height at the proximal adjacent segment. The pooled results showed that the Dynesys group was insignificantly different from the fusion group in terms of the disc height at the surgical segment (MD = -0.53, 95% CI of -1.30 to 0.23, P=0.170,  $I^2=83\%$ ; Additional file 4: Fig. S1A) and the disc height at the proximal adjacent segment (MD = -0.23, 95% CI



Fig. 3 Forest plots of Dynesys stabilization versus instrumented fusion: (A) screw loosening; (B) screw breakage; (C) surgical revision

of - 0.66 to 0.20, P = 0.300,  $I^2 = 0\%$ ; Additional file 4: Fig. S1B).

## Discussion

Spine fusion is a primary therapy for spinal degenerative diseases, but this method is associated with several complications, especially the acceleration of ASP [1, 5, 13]. In response to the complications caused by fusion, dynamic stabilization techniques have been developed, including DS, which is a widely used non-fusion technique with the advantage of ASP prevention [3].

Many studies have confirmed the safety and clinical equivalence of DS to fusion method. [4, 21, 24, 36] DS relieves clinical symptoms and improves the functional status and fusion instruments with durations of follow-up ranging from 28.78 months to 70.14 months [7, 15, 16, 20, 26]. Furthermore, Bredin et al. [35] performed a study with a follow-up of 93.6 months and concluded that the DS group showed substantial improvements in VAS and ODI scores compared with the fusion method. The fusion method is likely to be chosen in the retrospective cases, in which a more severe disease state is present. Additionally, patients with far lateral discs or other

А

Study or Subgroup         Events         Total         Events         Total         Weight         M-H, Fixed, 95% Cl Year         M-H, Fixed, 95% Cl           Silvestre 2014         0         32         3         25         5.5%         0.10 [0.00, 2.01]         2014           Zhang 2016         6         46         15         50         17.9%         0.35 [0.12, 1.00]         2016           Bredin 2017         4         33         9         25         12.9%         0.25 [0.07, 0.92]         2017           Wu 2017         0         26         1         31         1.9%         0.38 [0.01, 9.82]         2017           Wu 2017         0         26         15         23         16.3%         0.46 [0.17, 1.26]         2018           Zheng 2021         2         39         111         30         16.9%         0.09 [0.02, 0.46]         2021           Zhang 2021         3         23         11         20         14.7%         0.12 [0.03, 0.55]         2021           Total (95% Cl)         293         248         100.0%         0.24 [0.15, 0.39]         0.01         0.1         10         100           Dynesys         Fusion         Odds Ratio         Odds Ratio	А	Dynes	sys	Fusic	on		Odds Ratio		Odds	Ratio	
Silvestre 2014 0 32 3 25 5.5% 0.10 [0.00, 2.01] 2014 Zhang 2016 6 46 15 50 17.9% 0.35 [0.12, 1.00] 2016 Bredin 2017 4 33 9 25 12.9% 0.25 [0.07, 0.92] 2017 Wu 2017 0 26 1 31 1.9% 0.38 [0.01, 9.82] 2017 Ren 2018 2 38 11 44 13.8% 0.17 [0.03, 0.81] 2018 Kuo 2018 26 56 15 23 16.3% 0.46 [0.17, 1.26] 2018 Zhang 2021 2 39 11 30 16.9% 0.09 [0.02, 0.46] 2021 Zhang 2021 2 39 11 30 16.9% 0.09 [0.02, 0.46] 2021 Total (95% Cl) 293 248 100.0% 0.24 [0.15, 0.39] Total events 43 76 Heterogeneity: Chi <sup>2</sup> = 4.85, df = 7 (P = 0.68); l <sup>2</sup> = 0% Test for overall effect: Z = 5.65 (P < 0.0001) B Dynesys Fusion B Dynesys Fusion B Dynesys Fusion B Dynesys Fusion B Dynesys Fusion Study or Subgroup Events Total Events Total Weight M-H, Fixed. 95% Cl Year M-H, Fixed. 95% C	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI Year		M-H, Fixe	d, 95% Cl	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Silvestre 2014	0	32	3	25	5.5%	0.10 [0.00, 2.01] 2014	<	-		
Bredin 2017       4       33       9       25       12.9% $0.25 [0.07, 0.92]$ 2017         Wu 2017       0       26       1       31       1.9% $0.38 [0.01, 9.82]$ 2017         Ren 2018       2       38       11       44       13.8% $0.17 [0.03, 0.81]$ 2018         Zheng 2021       2       39       11       30       16.9% $0.09 [0.02, 0.46]$ 2021         Zhang 2021       3       23       11       20       14.7% $0.12 [0.03, 0.55]$ 2021         Total (95% CI)       293       248       100.0% $0.24 [0.15, 0.39]$ $0.01$ $0.01$ $0.1$ $100$ B       Dynesys       Fusion       Odds Ratio       Odds Ratio       Odds Ratio         Study or Subgroup       Events       Total       Events       Total       Weight       M-H, Fixed, 95% CI Year       M-H, Fixed, 95% CI         Yang 2014       1       30       2       45       18.8% $0.74 [0.06, 8.56]$ 2014       Image: Close Clo	Zhang 2016	6	46	15	50	17.9%	0.35 [0.12, 1.00] 2016				
Wu 2017       0       26       1       31       1.9%       0.38 [0.01, 9.82]       2017         Ren 2018       2       38       11       44       13.8%       0.17 [0.03, 0.81]       2018         Kuo 2018       26       56       15       23       16.3%       0.46 [0.17, 1.26]       2018         Zheng 2021       2       39       11       30       16.9%       0.09 [0.02, 0.46]       2021         Zhang 2021       3       23       11       20       14.7%       0.12 [0.03, 0.55]       2021         Total (95% CI)       293       248       100.0%       0.24 [0.15, 0.39]	Bredin 2017	4	33	9	25	12.9%	0.25 [0.07, 0.92] 2017				
Ren 2018       2       38       11       44       13.8% $0.17 [0.03, 0.81]$ 2018         Kuo 2018       26       56       15       23       16.3% $0.46 [0.17, 1.26]$ 2018         Zheng 2021       2       39       11       30       16.9% $0.09 [0.02, 0.46]$ 2021         Zhang 2021       3       23       11       20       14.7% $0.12 [0.03, 0.55]$ 2021         Total (95% CI)       293       248       100.0%       0.24 [0.15, 0.39] $0.01$ $0.01$ $0.11$ $10$ $100$ Total events       43       76 $0.01$ $0.11$ $10.01$ $0.01$ $0.11$ $100$ Dynesys       Fusion       Odds Ratio       Odds Ratio       Odds Ratio       Odds Ratio         Study or Subgroup       Events       Total       Events       Total       Weight       M-H, Fixed, 95% CI Year       M-H, Fixed, 95% CI         Yang 2014       1       30       2       45       18.8% $0.74 [0.06, 8.56]$ 2014       Image: Colored Colore	Wu 2017	0	26	1	31	1.9%	0.38 [0.01, 9.82] 2017				
Kuo 2018       26       56       15       23       16.3% $0.46$ [0.17, 1.26]       2018         Zheng 2021       2       39       11       30       16.9% $0.09$ [0.02, 0.46]       2021         Zhang 2021       3       23       11       20       14.7% $0.12$ [0.03, 0.55]       2021         Total (95% CI)       293       248       100.0% $0.24$ [0.15, 0.39]         Total events       43       76         Heterogeneity: Chi <sup>2</sup> = 4.85, df = 7 (P = 0.68); l <sup>2</sup> = 0%       0.01       0.1       1       10       100         Dynesys       Fusion       Odds Ratio       Odds Ratio       Odds Ratio       Odds Ratio       M-H. Fixed, 95% CI	Ren 2018	2	38	11	44	13.8%	0.17 [0.03, 0.81] 2018	_			
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Kuo 2018	26	56	15	23	16.3%	0.46 [0.17, 1.26] 2018			-	
Zhang 2021       3       23       11       20       14.7% $0.12 [0.03, 0.55]$ 2021         Total (95% CI)       293       248       100.0% $0.24 [0.15, 0.39]$ Total events       43       76         Heterogeneity: Chi <sup>2</sup> = 4.85, df = 7 (P = 0.68); l <sup>2</sup> = 0%       0.01       0.1       1       10       100         B       Dynesys       Fusion       Odds Ratio       M-H, Fixed, 95% CI Year       M-H, Fixed, 95% CI       M-H, Fixed, 95% CI         Yang 2014       1       30       2       45       18.8%       0.74 [0.06, 8.56]       2014         Zhang 2016       0       46       1       50       17.3%       0.35 [0.01, 8.93]       2016         Bredin 2017       1       33       2       25       26.8%       0.36 [0.03, 4.20]       2017         Zhang 2021       123       3       20       37.2%       0.26 [0.02, 2.70]       2021         Total (95% CI)       132       140       100.0%       0.39 [0.11, 1.40]       0.01       0.1       1       10       100         Total (95% CI)       132       140       100.0%       0.39 [0.11, 1.40]       0.01       0.1       1       10       100	Zheng 2021	2	39	11	30	16.9%	0.09 [0.02, 0.46] 2021				
Total (95% Cl)       293       248       100.0%       0.24 [0.15, 0.39]         Total events       43       76         Heterogeneity: Chi <sup>2</sup> = 4.85, df = 7 (P = 0.68); l <sup>2</sup> = 0%       0.01       0.1       100         Test for overall effect: Z = 5.65 (P < 0.0001)	Zhang 2021	3	23	11	20	14.7%	0.12 [0.03, 0.55] 2021				
Total (95% Cl)       293       248       100.0%       0.24 [0.15, 0.39]         Total events       43       76         Heterogeneity: Chi <sup>2</sup> = 4.85, df = 7 (P = 0.68); l <sup>2</sup> = 0%       0.01       0.1       1       100         Test for overall effect: Z = 5.65 (P < 0.00001)									•		
Total events       43       76         Heterogeneity: $Chi^2 = 4.85$ , $df = 7$ (P = 0.68); $ ^2 = 0\%$ 0.01       0.1       1       100         B       Dynesys       Fusion       Odds Ratio       M-H, Fixed, 95% Cl Year       Odds Ratio         Yang 2014       1       30       2       45       18.8%       0.74 [0.06, 8.56]       2014         Zhang 2016       0       46       1       50       17.3%       0.35 [0.01, 8.93]       2016         Bredin 2017       1       33       2       25       26.8%       0.36 [0.03, 4.20]       2017         Zhang 2021       1       23       3       20       37.2%       0.26 [0.02, 2.70]       2021         Total (95% Cl)       132       140       100.0%       0.39 [0.11, 1.40]       0.01       0.1       1       10       100         Total events       3       8       8       90.01       0.1       10       100       100	Total (95% CI)		293		248	100.0%	0.24 [0.15, 0.39]		•		
Heterogeneity: Chi <sup>2</sup> = 4.85, df = 7 (P = 0.68); l <sup>2</sup> = 0%         Test for overall effect: Z = 5.65 (P < 0.00001)         Odds Ratio         Odds Ratio         Odds Ratio         Study or Subgroup       Events Total       Weight       M-H, Fixed, 95% Cl Year         Yang 2014       1       30       2       45       18.8%       0.74 [0.06, 8.56]       2014         Zhang 2016       0       46       1       50       17.3%       0.35 [0.01, 8.93]       2016         Bredin 2017       1       33       2       25       26.8%       0.36 [0.03, 4.20]       2017         Total (95% Cl)         Total (95% Cl)       132       140       100.0%       0.39 [0.11, 1.40]         Total (95% Cl)       132       140       100.0%       0.39 [0.11, 1.40]         Total (95% Cl)       10       100       100         Total (95% Cl)       132       140       100.0%       0.39 [0.11, 1.40]       0.01       0.01       0.01       0.01       0.01       0.01	Total events	43		76							
Test for overall effect: $Z = 5.65$ (P < 0.00001)       Total register of the second stress	Heterogeneity: Chi <sup>2</sup> = 4	.85, df =	7 (P = 0	0.68); I <sup>2</sup> =	0%				10	100	
B       Dynesys       Fusion       Odds Ratio       Odds Ratio         Study or Subgroup       Events       Total       Events       Total       Weight       M-H, Fixed, 95% Cl Year       M-H, Fixed, 95% Cl Year         Yang 2014       1       30       2       45       18.8%       0.74 [0.06, 8.56]       2014         Zhang 2016       0       46       1       50       17.3%       0.35 [0.01, 8.93]       2016         Bredin 2017       1       33       2       25       26.8%       0.36 [0.03, 4.20]       2017         Zhang 2021       1       23       3       20       37.2%       0.26 [0.02, 2.70]       2021         Total (95% Cl)       132       140       100.0%       0.39 [0.11, 1.40]       0.01       0.1       10         Total events       3       8       8       0.01       0.1       10       100	Test for overall effect: 2	P < 0.0	0001)				0.01		Fusion	100	
B       Dynesys       Fusion       Odds Ratio       Odds Ratio         Study or Subgroup       Events       Total       Events       Total       Weight       M-H, Fixed, 95% Cl Year       M-H, Fixed, 95% Cl         Yang 2014       1       30       2       45       18.8% $0.74 [0.06, 8.56]$ 2014       Image: Control of the state of the									Dynesys	1 031011	
Study or Subgroup         Events         Total         Events         Total         Weight         M-H, Fixed, 95% Cl Year         M-H, Fixed, 95% Cl           Yang 2014         1         30         2         45         18.8%         0.74 [0.06, 8.56]         2014           Zhang 2016         0         46         1         50         17.3%         0.35 [0.01, 8.93]         2016           Bredin 2017         1         33         2         25         26.8%         0.36 [0.03, 4.20]         2017           Zhang 2021         1         23         3         20         37.2%         0.26 [0.02, 2.70]         2021           Total (95% Cl)         132         140         100.0%         0.39 [0.11, 1.40]         Image: the second secon	В	Dynes	sys	Fusic	on		Odds Ratio		Odds	Ratio	
Yang 2014       1       30       2       45       18.8% $0.74 [0.06, 8.56]$ 2014         Zhang 2016       0       46       1       50       17.3% $0.35 [0.01, 8.93]$ 2016         Bredin 2017       1       33       2       25       26.8% $0.36 [0.03, 4.20]$ 2017         Zhang 2021       1       23       3       20       37.2% $0.26 [0.02, 2.70]$ 2021         Total (95% CI)       132       140       100.0% $0.39 [0.11, 1.40]$ $0.01$ $0.1$ $10$ Total events       3       8 $0.01$ $0.1$ $10$ $100$	Study or Subgroup	Events	Total	Events	Total						
Zhang 2016       0       46       1       50       17.3% $0.35 [0.01, 8.93]$ 2016         Bredin 2017       1       33       2       25       26.8% $0.36 [0.03, 4.20]$ 2017         Zhang 2021       1       23       3       20       37.2% $0.26 [0.02, 2.70]$ 2021         Total (95% CI)       132       140       100.0% $0.39 [0.11, 1.40]$ Total events       3       8 $0.01$ $0.1$ 1 $10$ $100$				Liono	Total	Weight	M-H, Fixed, 95% CI Year		<u>M-H, Fixe</u>	d, 95% Cl	
Bredin 2017       1       33       2       25       26.8% $0.36$ [ $0.03, 4.20$ ]       2017         Zhang 2021       1       23       3       20       37.2% $0.26$ [ $0.02, 2.70$ ]       2021         Total (95% CI)       132       140       100.0% $0.39$ [ $0.11, 1.40$ ]         Total events       3       8         Heterogeneity: Chi <sup>2</sup> = 0.39, df = 3 (P = 0.94); l <sup>2</sup> = 0%       0.01       0.1       1       10       100	Yang 2014	1	30	2	45	18.8%	<u>M-H, Fixed, 95% Cl Year</u> 0.74 [0.06, 8.56] 2014		M-H, Fixe	d, 95% Cl	
Zhang 2021       1       23       3       20       37.2%       0.26 [0.02, 2.70]       2021         Total (95% CI)       132       140       100.0%       0.39 [0.11, 1.40]         Total events       3       8         Heterogeneity: Chi <sup>2</sup> = 0.39, df = 3 (P = 0.94); l <sup>2</sup> = 0%       0.01       0.1       1       10       100	Yang 2014 Zhang 2016	1 0	30 46	2 1	45 50	18.8% 17.3%	0.74 [0.06, 8.56] 2014 0.35 [0.01, 8.93] 2016		M-H, Fixe	d, 95% Cl	
Total (95% CI)       132       140       100.0%       0.39 [0.11, 1.40]         Total events       3       8         Heterogeneity: Chi <sup>2</sup> = 0.39, df = 3 (P = 0.94); l <sup>2</sup> = 0%       0.01       0.1       1       10         Total events       7       7       0.41 (D = 0.45)       0.01       0.1       1       10	Yang 2014 Zhang 2016 Bredin 2017	1 0 1	30 46 33	2 1 2	45 50 25	Weight 18.8% 17.3% 26.8%	M-H, Fixed, 95% CI Year           0.74 [0.06, 8.56]         2014           0.35 [0.01, 8.93]         2016           0.36 [0.03, 4.20]         2017		M-H, Fixe	<u></u>	
Total (95% CI)         132         140         100.0%         0.39 [0.11, 1.40]           Total events         3         8           Heterogeneity: Chi <sup>2</sup> = 0.39, df = 3 (P = 0.94); l <sup>2</sup> = 0%         0.01         0.1         1         100           Total events         3         8         100.0%         0.39 [0.11, 1.40]         100	Yang 2014 Zhang 2016 Bredin 2017 Zhang 2021	1 0 1 1	30 46 33 23	2 1 2 3	45 50 25 20	Weight 18.8% 17.3% 26.8% 37.2%	M-H, Fixed, 95% CI Year           0.74 [0.06, 8.56]         2014           0.35 [0.01, 8.93]         2016           0.36 [0.03, 4.20]         2017           0.26 [0.02, 2.70]         2021		M-H, Fixe	<u></u>	
Total events     3     8       Heterogeneity: Chi <sup>2</sup> = 0.39, df = 3 (P = 0.94); l <sup>2</sup> = 0%     0.01     0.1     1       Total for growth     0.01     0.1     1     100	Yang 2014 Zhang 2016 Bredin 2017 Zhang 2021	1 0 1 1	30 46 33 23	2 1 2 3	45 50 25 20	Weight 18.8% 17.3% 26.8% 37.2%	M-H, Fixed, 95% CI Year           0.74 [0.06, 8.56]         2014           0.35 [0.01, 8.93]         2016           0.36 [0.03, 4.20]         2017           0.26 [0.02, 2.70]         2021		M-H, Fixe	.d. 95% Cl	
Heterogeneity: Chi <sup>2</sup> = 0.39, df = 3 (P = 0.94); l <sup>2</sup> = 0% Test for suprell effect: <b>Z</b> = 1.44 (P = 0.45) 0.01 0.1 1 10 100	Yang 2014 Zhang 2016 Bredin 2017 Zhang 2021 Total (95% CI)	1 0 1 1	30 46 33 23 <b>132</b>	2 1 2 3	45 50 25 20 <b>140</b>	Weight           18.8%           17.3%           26.8%           37.2%           100.0%	M-H, Fixed, 95% CI Year           0.74 [0.06, 8.56]         2014           0.35 [0.01, 8.93]         2016           0.36 [0.03, 4.20]         2017           0.26 [0.02, 2.70]         2021           0.39 [0.11, 1.40]         1.40		M-H, Fixe	<u>.d. 95% Cl</u>	
Test for everall effects 7 = 1.44 (D = 0.15)	Yang 2014 Zhang 2016 Bredin 2017 Zhang 2021 Total (95% CI) Total events	1 0 1 1 3	30 46 33 23 <b>132</b>	2 1 2 3 8	45 50 25 20 140	Weight 18.8% 17.3% 26.8% 37.2% 100.0%	M-H, Fixed, 95% CI Year           0.74 [0.06, 8.56]         2014           0.35 [0.01, 8.93]         2016           0.36 [0.03, 4.20]         2017           0.26 [0.02, 2.70]         2021           0.39 [0.11, 1.40]         1.40		M-H, Fixe	<u>d. 95% Cl</u>	
Test for overall effect. $Z = 1.44$ (P = 0.15) Dynesvs Eusion	Yang 2014 Zhang 2016 Bredin 2017 Zhang 2021 <b>Total (95% CI)</b> Total events Heterogeneity: Chi <sup>2</sup> = 0	1 0 1 1 3 0.39, df =	30 46 33 23 <b>132</b> 3 (P = 0	2 1 2 3 3 0.94);   <sup>2</sup> =	45 50 25 20 <b>140</b> 0%	Weight 18.8% 17.3% 26.8% 37.2% 100.0%	M-H, Fixed, 95% CI Year           0.74 [0.06, 8.56]         2014           0.35 [0.01, 8.93]         2016           0.36 [0.03, 4.20]         2017           0.26 [0.02, 2.70]         2021           0.39 [0.11, 1.40]         140	 	M-H, Fixe		

Fig. 4 Forest plots of Dynesys stabilization versus instrumented fusion: (A) ASDeg; (B) ASDis

A       Dynesys       Fusion       Mean Difference       Mean Difference         Study or Subgroup       Mean       SD       Total       Weight       IV. Random, 95% CI       IV. Random, 95% CI         Yang 2014       2.97       0.12       30       1.25       0.16       45       21.4%       1.72 [1.66, 1.78]       2014         Fei 2015       3.7       1.4       95       0.6       0.6       81       21.2%       3.10 [2.79, 3.41]       2015       •       •         Bredin 2017       4.1       2       3       0.7       0.5       25       20.2%       3.40 [2.69, 4.11]       2018       •       •         Luo 2022       11.7       4.3       34       0.8       0.26       31       17.3%       10.90 [9.45, 12.35]       2022         Total (95% CI)       248       205       100.0%       3.87 [2.50, 5.24]       •		_			_										
Study or Subgroup       Mean       SD       Total       Weight       IV. Random, 95% CI       Year       IV. Random, 95% CI         Yang 2014       2.97       0.12       30       1.25       0.16       45       21.4%       1.72 [1.66, 1.78]       2014       2014         Fei 2015       3.7       1.4       95       0.6       0.6       81       21.2%       3.10 [2.79, 3.41]       2015         Bredin 2017       4.1       2       33       0.7       0.5       25       20.2%       3.40 [2.69, 4.11]       2017         Kuo 2018       1.4       2.5       56       0       1.1       23       20.0%       1.40 [0.61, 2.19]       2018         Luo 2022       11.7       4.3       34       0.8       0.26       31       17.3%       10.90 [9.45, 12.35]       2022         Total (95% CI)       248       205       100.0%       3.87 [2.50, 5.24]       -10       -5       5       10         B       Dynesys       Fusion       Mean Difference       Mean Difference       Mean Difference       Mean Difference       V. Random, 95% CI       Y. Random, 95% CI	А	D	nesys	;	F	usion			Mean Difference			Mea	n Differe	nce	
Yang 20142.970.12301.250.164521.4%1.72 [1.66, 1.78]2014Fei 20153.71.4950.60.68121.2%3.10 [2.79, 3.41]2015Bredin 20174.12330.70.52520.2%3.40 [2.69, 4.11]2017Kuo 20181.42.55601.12320.0%1.40 [0.61, 2.19]2018Luo 202211.74.3340.80.263117.3%10.90 [9.45, 12.35]2022Total (95% CI)248205100.0%3.87 [2.50, 5.24]Heterogeneity: Tau² = 2.28; Chi² = 245.64, df = 4 (P < 0.00001); i² = 98%	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year		IV, Ra	<u>ındom, 9</u>	5% CI	
Fei 2015       3.7       1.4       95       0.6       0.6       81       21.2%       3.10 [2.79, 3.41]       2015         Bredin 2017       4.1       2       33       0.7       0.5       25       20.2%       3.40 [2.69, 4.11]       2017         Kuo 2018       1.4       2.5       56       0       1.1       23       20.0%       1.40 [0.61, 2.19]       2018         Luo 2022       11.7       4.3       34       0.8       0.26       31       17.3%       10.90 [9.45, 12.35]       2022         Total (95% Cl)       248       205       100.0%       3.87 [2.50, 5.24]         Heterogeneity: Tau <sup>2</sup> = 2.28; Chi <sup>2</sup> = 245.64, df = 4 (P < 0.00001); l <sup>2</sup> = 98%       Mean Difference       Mean Difference         Study or Subgroup       Mean       SD Total       Mean       SD Total       Weight       IV. Random.95% Cl Year       IV. Random.95% Cl         Yang 2014       8.22       0.25       30       8.44       0.59       45       17.1%       -0.22 [-0.41, -0.03]       2014         Wu 2017       8.3       1.65       26       10.86       2.09       31       14.4%       -2.66 [-3.53, -1.59]       2017         Hu 2019       5.37       2.51       22	Yang 2014	2.97	0.12	30	1.25	0.16	45	21.4%	1.72 [1.66, 1.78]	2014					
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Fei 2015	3.7	1.4	95	0.6	0.6	81	21.2%	3.10 [2.79, 3.41]	2015					
Kuo 20181.42.55601.12320.0%1.40 [0.61, 2.19]2018Luo 202211.74.3340.80.263117.3%10.90 [9.45, 12.35]2022Total (95% Cl)248205100.0%3.87 [2.50, 5.24]Heterogeneity: Tau <sup>2</sup> = 2.28; Chi <sup>2</sup> = 245.64, df = 4 (P < 0.00001); l <sup>2</sup> = 98%3.87 [2.50, 5.24]Test for overall effect: Z = 5.55 (P < 0.00001)	Bredin 2017	4.1	2	33	0.7	0.5	25	20.2%	3.40 [2.69, 4.11]	2017			· ·	-	
Luo 2022 11.7 4.3 34 0.8 0.26 31 17.3% 10.90 [9.45, 12.35] 2022 Total (95% CI) 248 205 100.0% Heterogeneity: Tau <sup>2</sup> = 2.28; Chi <sup>2</sup> = 245.64, df = 4 (P < 0.00001); I <sup>2</sup> = 98% Test for overall effect: Z = 5.55 (P < 0.00001) B Dynesys Fusion Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% CI Year Yang 2016 9.5 0.6 45 11.1 0.7 40 17.0% -0.22 [-0.41, -0.03] 2014 Wang 2016 10.1 2.7 46 13.1 3.1 50 13.5% -3.00 [-4.16, -1.84] 2016 Wu 2017 8.3 1.65 26 10.86 2.09 31 14.4% -2.56 [-3.53, -1.59] 2017 Hu 2019 5.37 2.51 22 7.86 2.12 44 13.2% -2.49 [-3.71, -1.27] 2019 Zhang 2021 5.05 2.06 39 7.45 2.45 40 14.3% -2.40 [-3.40, -1.40] 2021 Zhang 2021 10.5 2.3 23 13.6 3.4 20 10.5% -3.10 [-4.86, -1.34] 2021 Total (95% CI) 231 270 100.0% Total (95% CI) 231 270 100.0% Test for overall effect: Z = 4.49 (P < 0.00001); I <sup>2</sup> = 95%	Kuo 2018	1.4	2.5	56	0	1.1	23	20.0%	1.40 [0.61, 2.19]	2018			-		
Total (95% CI)248205100.0% $3.87$ [2.50, 5.24]Heterogeneity: Tau² = 2.28; Chi² = 245.64, df = 4 (P < 0.00001); I² = 98% Test for overall effect: Z = 5.55 (P < 0.0001)	Luo 2022	11.7	4.3	34	0.8	0.26	31	17.3%	10.90 [9.45, 12.35]	2022					
Total (95% Cl)248205<100.0% $3.87$ [2.50, 5.24]Heterogeneity: Tau <sup>2</sup> = 2.28; Chi <sup>2</sup> = 245.64, df = 4 (P < 0.00001); I <sup>2</sup> = 98%-10-50510BDynesysFusionMean DifferenceMean DifferenceMean DifferenceIV, Random, 95% ClYearYang 20148.220.25308.440.594517.1%-0.22 [-0.41, -0.03]2014Wang 20169.50.64511.10.74017.0%-1.60 [-1.88, -1.32]2016Zhang 201610.12.74613.13.15013.5%-3.00 [-4.16, -1.84]2016Wu 20178.31.652610.862.093114.4%-2.49 [-3.71, -1.27]2019Hu 20195.372.51227.862.124413.2%-2.49 [-3.71, -1.27]2019Zhang 20215.052.06397.452.454014.3%-2.40 [-3.40, -1.40]2021Total (95% Cl)231231270100.0%-3.10 [-4.86, -1.34]2021Total (95% Cl)231231270100.0%-2.08 [-2.99, -1.17]Heterogeneity: Tau <sup>2</sup> = 1.24; Chi <sup>2</sup> = 115.75, df = 6 (P < 0.00001); I <sup>2</sup> = 95%-2.08 [-2.99, -1.17]Heterogeneity: Tau <sup>2</sup> = 1.24; Oh (P < 0.00001)															
Heterogeneity: $Tau^2 = 2.28$ ; $Chi^2 = 245.64$ , $df = 4$ (P < 0.00001); $ ^2 = 98\%$ Test for overall effect: Z = 5.55 (P < 0.00001) B <u>Dynesys</u> Fusion Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% Cl Year Yang 2014 8.22 0.25 30 8.44 0.59 45 17.1% -0.22 [-0.41, -0.03] 2014 Wang 2016 9.5 0.6 45 11.1 0.7 40 17.0% -1.60 [-1.88, -1.32] 2016 Zhang 2016 10.1 2.7 46 13.1 3.1 50 13.5% -3.00 [-4.16, -1.84] 2016 Wu 2017 8.3 1.65 26 10.86 2.09 31 14.4% -2.56 [-3.53, -1.59] 2017 Hu 2019 5.37 2.51 22 7.86 2.12 44 13.2% -2.49 [-3.71, -1.27] 2019 Zheng 2021 5.05 2.06 39 7.45 2.45 40 14.3% -2.40 [-3.40, -1.40] 2021 Zhang 2021 10.5 2.3 23 13.6 3.4 20 10.5% -3.10 [-4.86, -1.34] 2021 Total (95% Cl) 231 270 100.0% -2.08 [-2.99, -1.17] Heterogeneity: $Tau^2 = 1.24$ ; $Chi^2 = 115.75$ , $df = 6$ (P < 0.00001); $ ^2 = 95\%$ Test for overall effect: Z = 4.49 (P < 0.00001)	Total (95% CI)			248			205	100.0%	3.87 [2.50, 5.24]						
Test for overall effect: $Z = 5.55$ (P < 0.00001)DynesysFusionMean DifferenceMean DifferenceMean DifferenceStudy or SubgroupMean SD Total Mean SD Total WeightIV. Random. 95% CI YearYang 20148.220.25308.440.594517.1% $-0.22$ [-0.41, $-0.03$ ] 2014Image: Colspan="6">Wean DifferenceYang 20169.50.64511.10.74017.0% $-1.60$ [-1.88, $-1.32$ ] 2016Image: Colspan="6">Image: Colspan="6">IV. Random. 95% CIYang 20169.50.64511.10.74017.0% $-1.60$ [-1.88, $-1.32$ ] 2016Image: Colspan="6">Image: Colspan="6">IV. Random. 95% CIYang 20169.50.64511.10.74017.0% $-1.60$ [-1.88, $-1.32$ ] 2016Image: Colspan="6">Image: Colspan="6">Image: Colspan="6">Image: Colspan="6">Image: Colspan="6">Nean DifferenceWu 20178.31.652.610.862.093114.4% $-2.56$ [-3.53, $-1.59$ ] 2017Hu 20195.372.51227.862.124413.2% $-2.40$ [-3.40, $-1.40$ ] 2021Zhang 202110.52.32.313.63.42010.5% $-3.10$ [-4.86, $-1.34$ ] 2021Zhang 202110.52.32.313.63.42010.5% $-3.10$ [-4.86, $-1.34$ ] 2021Total (95% CI)231270100.0% $-2.08$ [-2.99, $-1.17$ ] $-4$ $-2$ $0$ <td>Heterogeneity: Tau<sup>2</sup> =</td> <td>2.28; Cł</td> <td>1i² = 24</td> <td>5.64, 0</td> <td>if = 4 (F</td> <td><b>o</b> &lt; 0.0</td> <td>0001);  </td> <td>² = 98%</td> <td></td> <td>_</td> <td>-10</td> <td>-5</td> <td>0</td> <td>5</td> <td>10</td>	Heterogeneity: Tau <sup>2</sup> =	2.28; Cł	1i² = 24	5.64, 0	if = 4 (F	<b>o</b> < 0.0	0001);	² = 98%		_	-10	-5	0	5	10
B         Dynesys         Fusion         Mean Difference         Mean Difference           Study or Subgroup         Mean         SD         Total         Mean         SD         Total         Weight         IV. Random, 95% CI Year         IV. Random, 95% CI           Yang 2014         8.22         0.25         30         8.44         0.59         45         17.1%         -0.22 [-0.41, -0.03]         2014           Wang 2016         9.5         0.6         45         11.1         0.7         40         17.0%         -1.60 [-1.88, -1.32]         2016           Zhang 2016         10.1         2.7         46         13.1         3.1         50         13.5%         -3.00 [-4.16, -1.84]         2016           Wu 2017         8.3         1.65         26         10.86         2.09         31         14.4%         -2.26 [-3.53, -1.59]         2017           Hu 2019         5.37         2.51         22         7.86         2.12         44         13.2%         -2.40 [-3.40, -1.40]         2021           Zhang 2021         5.05         2.06         39         7.45         2.45         40         14.3%         -2.40 [-3.40, -1.40]         2021           The grow of the e c c control         2.	Test for overall effect:	Z = 5.55	5 (P < 0	0.00001	)						-10	Dyne	sys Fus	ion	10
Study or SubgroupMeanSDTotalMeanSDTotalWeightIV, Random, 95% Cl YearIV, Random, 95% ClYang 20148.220.25308.440.594517.1% $-0.22$ [-0.41, $-0.03$ ]2014Wang 20169.50.64511.10.74017.0% $-1.60$ [-1.88, $-1.32$ ]2016Zhang 201610.12.74613.13.15013.5% $-3.00$ [-4.16, $-1.84$ ]2016Wu 20178.31.652610.862.093114.4% $-2.49$ [-3.71, $-1.27$ ]2019Hu 20195.372.51227.862.124413.2% $-2.49$ [-3.71, $-1.27$ ]2019Zhang 20215.052.06397.452.454014.3% $-2.40$ [-3.40, $-1.40$ ]2021Zhang 202110.52.32313.63.42010.5% $-3.10$ [-4.86, $-1.34$ ]2021Total (95% Cl)231231270100.0% $-2.08$ [-2.99, $-1.17$ ] $-4$ $-2$ $0$ $2$ $4$ Heterogeneity: Tau <sup>2</sup> = 1.24; Chi <sup>2</sup> = 115.75, df = 6 (P < 0.00001); I <sup>2</sup> = 95%Test for overall effect: Z = 4.49 (P < 0.00001)	В	Dy	nesys	5	F	usion			Mean Difference			Mea	n Differe	nce	
Yang 20148.220.25308.440.594517.1% $-0.22$ [-0.41, $-0.03$ ]2014Wang 20169.50.64511.10.74017.0% $-1.60$ [-1.88, $-1.32$ ]2016Zhang 201610.12.74613.13.15013.5% $-3.00$ [-4.16, $-1.84$ ]2016Wu 20178.31.652610.862.093114.4% $-2.56$ [-3.53, $-1.59$ ]2017Hu 20195.372.51227.862.124413.2% $-2.49$ [-3.71, $-1.27$ ]2019Zheng 20215.052.06397.452.454014.3% $-2.40$ [-3.40, $-1.40$ ]2021Zhang 202110.52.32313.63.42010.5% $-3.10$ [-4.86, $-1.34$ ]2021Total (95% CI)231270100.0% $-2.08$ [-2.99, $-1.17$ ] $-4$ $-2$ $0$ $2$ $4$ Heterogeneity: Tau <sup>2</sup> = 1.24; Chi <sup>2</sup> = 115.75, df = 6 (P < 0.00001); l <sup>2</sup> = 95%Test for overall effect: Z = 4.49 (P < 0.00001)	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year		IV, Ra	ndom, 9	5% CI	
Wang 2016       9.5       0.6       45       11.1       0.7       40       17.0%       -1.60 [-1.88, -1.32]       2016         Zhang 2016       10.1       2.7       46       13.1       3.1       50       13.5%       -3.00 [-4.16, -1.84]       2016         Wu 2017       8.3       1.65       26       10.86       2.09       31       14.4%       -2.56 [-3.53, -1.59]       2017         Hu 2019       5.37       2.51       22       7.86       2.12       44       13.2%       -2.49 [-3.71, -1.27]       2019         Zheng 2021       5.05       2.06       39       7.45       2.45       40       14.3%       -2.40 [-3.40, -1.40]       2021         Zhang 2021       10.5       2.3       23       13.6       3.4       20       10.5%       -3.10 [-4.86, -1.34]       2021         Total (95% CI)       231       270       100.0%       -2.08 [-2.99, -1.17]       -4       -2       0       2       4         Heterogeneity: Tau <sup>2</sup> = 1.24; Chi <sup>2</sup> = 115.75, df = 6 (P < 0.00001); l <sup>2</sup> = 95%       -5.08 [-2.99, -1.17]       -4       -2       0       2       4         Upmesys       Fusion       -4       -2       2       2       4 <th< td=""><td>Yang 2014</td><td>8.22</td><td>0.25</td><td>30</td><td>8.44</td><td>0.59</td><td>45</td><td>17.1%</td><td>-0.22 [-0.41, -0.03]</td><td>2014</td><td></td><td></td><td>-</td><td></td><td></td></th<>	Yang 2014	8.22	0.25	30	8.44	0.59	45	17.1%	-0.22 [-0.41, -0.03]	2014			-		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Wang 2016	9.5	0.6	45	11.1	0.7	40	17.0%	-1.60 [-1.88, -1.32]	2016		-			
Wu 2017       8.3       1.65       26       10.86       2.09       31       14.4%       -2.56       [-3.53, -1.59]       2017         Hu 2019       5.37       2.51       22       7.86       2.12       44       13.2%       -2.49       [-3.71, -1.27]       2019         Zheng 2021       5.05       2.06       39       7.45       2.45       40       14.3%       -2.40       [-3.40, -1.40]       2021         Zhang 2021       10.5       2.3       23       13.6       3.4       20       10.5%       -3.10       [-4.86, -1.34]       2021         Total (95% Cl)       231       270       100.0%       -2.08       [-2.99, -1.17]       -4       -2       0       2       4         Test for overall effect: Z = 4.49 (P < 0.00001)	Zhang 2016	10.1	2.7	46	13.1	3.1	50	13.5%	-3.00 [-4.16, -1.84]	2016	-				
Hu 2019 $5.37$ $2.51$ $22$ $7.86$ $2.12$ $44$ $13.2\%$ $-2.49$ $[-3.71, -1.27]$ $2019$ Zheng 2021 $5.05$ $2.06$ $39$ $7.45$ $2.45$ $40$ $14.3\%$ $-2.40$ $[-3.40, -1.40]$ $2021$ Zhang 2021 $10.5$ $2.3$ $23$ $13.6$ $3.4$ $20$ $10.5\%$ $-3.10$ $[-4.86, -1.34]$ $2021$ Total (95% Cl) $231$ $270$ $100.0\%$ $-2.08$ $[-2.99, -1.17]$ $-4$ $-2$ $0$ $2$ $4$ Heterogeneity: Tau <sup>2</sup> = 1.24; Chi <sup>2</sup> = 115.75, df = 6 (P < 0.00001); l <sup>2</sup> = 95\% $-4$ $-2$ $0$ $2$ $4$ Test for overall effect: Z = 4.49 (P < 0.00001)	Wu 2017	8.3	1.65	26	10.86	2.09	31	14.4%	-2.56 [-3.53, -1.59]	2017		•			
Zheng 2021 $5.05$ $2.06$ $39$ $7.45$ $2.45$ $40$ $14.3\%$ $-2.40$ $[-3.40, -1.40]$ $2021$ Zhang 2021 $10.5$ $2.3$ $23$ $13.6$ $3.4$ $20$ $10.5\%$ $-3.10$ $[-4.86, -1.34]$ $2021$ Total (95% Cl) $231$ $270$ $100.0\%$ $-2.08$ $[-2.99, -1.17]$ $-4$ $-2$ $0$ $2$ $4$ Heterogeneity: Tau <sup>2</sup> = 1.24; Chi <sup>2</sup> = 115.75, df = 6 (P < 0.00001); l <sup>2</sup> = 95\% $-4$ $-2$ $0$ $2$ $4$ Test for overall effect: Z = 4.49 (P < 0.00001) $Fusion$ $Fusion$ $-4$ $-2$ $0$ $2$ $4$	Hu 2019	5.37	2.51	22	7.86	2.12	44	13.2%	-2.49 [-3.71, -1.27]	2019		•			
Zhang 2021 $10.5$ $2.3$ $23$ $13.6$ $3.4$ $20$ $10.5\%$ $-3.10$ $[-4.86, -1.34]$ $2021$ Total (95% Cl) $231$ $270$ $100.0\%$ $-2.08$ $[-2.99, -1.17]$ Heterogeneity: Tau <sup>2</sup> = 1.24; Chi <sup>2</sup> = 115.75, df = 6 (P < 0.00001); l <sup>2</sup> = 95% $-4$ $-2$ $0$ $2$ $4$ Test for overall effect: Z = 4.49 (P < 0.00001)       Dynesys       Fusion	Zheng 2021	5.05	2.06	39	7.45	2.45	40	14.3%	-2.40 [-3.40, -1.40]	2021		•			
Total (95% Cl)       231       270       100.0%       -2.08 [-2.99, -1.17]         Heterogeneity: Tau <sup>2</sup> = 1.24; Chi <sup>2</sup> = 115.75, df = 6 (P < 0.00001); l <sup>2</sup> = 95%       -2.08 [-2.99, -1.17]       -4       -2       0       2       4         Test for overall effect: Z = 4.49 (P < 0.00001)	Zhang 2021	10.5	2.3	23	13.6	3.4	20	10.5%	-3.10 [-4.86, -1.34]	2021					
Heterogeneity: Tau <sup>2</sup> = 1.24; Chi <sup>2</sup> = 115.75, df = 6 (P < $0.00001$ ); l <sup>2</sup> = 95% Test for overall effect: Z = 4.49 (P < $0.00001$ )	Total (95% CI)			231			270	100.0%	-2.08 [-2.99, -1.17]						
Test for overall effect: $Z = 4.49$ (P < 0.00001)       -4       -2       0       2       4         Dynesys       Fusion	Heterogeneity: $Tau^2 =$	1 24. CH	$n^2 = 11$	5 75 6	If = 6 (E	~ ^ ^ ^	0001)	2 = 95%		_					
Dynesys Fusion	Test for overall effect:	7 = 4.40			1) – O (F	< 0.0	0001),	- 33 /0			-4	-2	0	2	4
	rescior overall effect.	2 - 4.49	, (F < (	.0000	)							Dynes	sys Fus	ion	
C Dynesys Fusion Mean Difference Mean Difference	С	Dy	nesys	;	Fι	ision			Mean Difference			Mear	Differe	nce	
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% Cl Year IV, Random, 95% Cl	Study or Subgroup	Mean	SD	Total	Mean	SD 1	Total \	Neight	IV, Random, 95% CI	Year		IV, Ra	<u>ndom, 9</u>	5% CI	

C	-,		•			•		moun Binoronoo			mou			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year		IV, Ra	andom, 95	5% CI	
Fei 2015	15.8	4.7	95	13.6	3.4	81	33.6%	2.20 [1.00, 3.40]	2015			-		
Bredin 2017	32.1	1.6	33	30.1	2	25	33.7%	2.00 [1.04, 2.96]	2017			•		
Luo 2022	28.8	7.3	34	8.3	1.6	31	32.7%	20.50 [17.98, 23.02]	2022					
Total (95% CI)			162			137	100.0%	8.12 [0.42, 15.81]						-
Heterogeneity: Tau <sup>2</sup> =	45.49; 0	Chi <sup>2</sup> =	189.10	), df = 2	! (P <	0.0000	01); I² = 99	%		-20	-10	0	10	20
Test for overall effect.	2 - 2.01	(F -	0.04)								Dyne	sys Fusi	on	

Fig. 5 Forest plots of Dynesys stabilization versus instrumented fusion: (A) ROM at stabilized segments; (B) ROM at proximal adjacent segment; (C) ROM of L1–S1 lumbar lordosis angle

pathology that required facetectomy and TLIF were not considered as candidates for DS because of the possibility of introducing confounding variables. Therefore, only the prospective studies that report the VAS and ODI scores were included for analyses, because these studies may effectively control the severity of diseases in this metaanalysis. In conclusion, DS remarkably improved the VAS scores for back and leg pain. No significant difference was observed in post-operative ODI scores between the two groups. The results may be explained as follows. Although the decompression of nerve roots was conducted in DS and fusion methods, the risk of nerve root injuries increased, because the latter not only dissects the bone and soft tissue but also requires the preparation of endplates and insertion of interbody devices or bone grafting, leading to back and leg pain after surgery. Additional surgical instrument and enlargement of surgical trauma in fusion method may increase the surgical time, blood loss, and in-hospital complications. Furthermore, the occurrence of non-fusion with fusion method would aggravate clinical symptoms in the later recovery process. Moreover, the Dynesys group did not differ from the fusion group in terms of screw loosening and breakage. These results can be attributed to the simplified operation of DS and the preservation of lumbar mobility. Hence, DS showed equivalent, or even better clinical measurements, compared with conventional fusion. The safety of DS has complied with the basic requirements for widespread clinical application in cases meeting indications, such as disc herniation, lumbar spinal stenosis, and grade I degenerative spondylolisthesis in lumbar.

DS is mainly used to minimize ASP. [6, 37] Hashimoto et al. [8] reported that the fusion of stabilized segments may increase the biomechanical stress on the adjacent levels, leading to ASDeg and ASDis. DS preserves the ROM at the stabilized segments and prevents hypermobility at the adjacent segments in the medium or longterm follow-up [4, 7, 15, 20, 21, 24, 36]. By contrast, Yang et al. [17] found that DS does not maintain the ROM at the adjacent segments compared with fusion method after a minimum follow-up of 24 months. Furthermore, Schaeren et al. [38] found no measurable motion at the stabilized segments after DS but reported signs of degeneration at adjacent segments in 47% patients after 4 years, thus supporting our findings from the use of fusion instrument. In the current meta-analysis, in the fusion group, the ROM at stabilized segments and the ROM of LL decreased remarkably, but the ROM at adjacent segments increased remarkably compared with those in the DS group. This result was obtained, possible because the DS pedicle screws are connected to the PET cords, thereby providing tension to limit excessive flexion and PCU spacers resisting compressive force to limit over extension; this phenomenon leads to reduced vertebral abnormal activity and preserved motion at the instrumental segments and hypermobility at the adjacent segments in the medium and long-term duration [39].

Another early radiographic manifestation of ASP in clinical practice is the narrowness and loss of the intervertebral space, and its height is commonly considered as an indicator to evaluate the degree of ASP [3, 15]. In the current meta-analysis, the Dynesys and fusion group did not differ in terms of disc heigh both at stabilized and adjacent segments. The results can be attributed to the natural degenerative progression of the disc at the stabilized and adjacent segments despite DS, and this phenomenon is not associated with the stabilization method [40, 41]. Thus, DS showed no advantage over fusion method in terms of prevention of disc degeneration after surgery.

Whether DS can delay the occurrence of ASP has not been confirmed. In the study of Bredin et al. [35], a mean follow-up of 5.5 years was obtained, and significantly less ASDeg was observed in the DS group than in the fusion group (12.1% versus 36%); Zhang et al. [24] confirmed the conclusion in their study with mean follow-up of 55.2 months. DS may not prevent ASDeg, with high rates ranging from 16 to 47% [37, 38, 42]. In the current meta-analysis, the Dynesys group showed a lower rate of ASDeg than the fusion group. Although DS showed no superiority in terms of preventing disc degeneration compared with fusion method, the former performed well in terms of sparing abnormal biomechanical load at the stabilized and adjacent segments, consequently preserving the physiological motion after stabilization; this finding may explain why DS can prevent ASDeg [10, 43]. Furthermore, the PET cords and PCU spacers were used to restrict flexion and extension. With increasing cord pretension, the flexion ROM at stabilized and adjacent levels increased, but the extension ROM decreased [44]. The realistic stiffness of DS varies with cord pretension and spacer length, which are decided based on surgeons' personal experience; this phenomenon might partly explain the conflicting results in previously published works [7, 45, 46].

The prevention of ASDis is crucial because of the potential risk of revision surgery and adverse effect on health care outcomes and cost. Our meta-analysis demonstrated that the Dynesys group showed less ASDis than the fusion group, whereas the difference was not significant. The result revealed that DS can prevent ASDeg instead of ASDis compared with the fusion method. The occurrence of ASDis is relatively lower than that of ASDeg, because ASDeg does not always cause clinical symptoms. Furthermore, the lack of remarkable difference in disabilities (ODI) post-operatively between the two methods indicate the similar incidence of ASDis after surgery.

Screw loosening is a common complication of DS. The current study also showed that the Dynesys group did not differ from the fusion group in terms of screw loosening and screw breakage. Ko et al. [47] included 71 patients and found that the screw loosening had no adverse effect on the improvement of VAS and ODI scores after the surgery. Hu et al. [48] investigated the mid- and longterm outcomes of hybrid surgery that combined Dynesys fusion and non-fusion stabilization in the treatment of degenerative lumbar diseases. The results show that screw loosening mainly occurred at the end of the fixed segment, and old age was a risk factor for screw loosening. Screw loosening is usually asymptomatic and can be observed regularly. If the symptoms related to screw loosening or screw breakage occur, and the conservative treatment fails, revision surgery is required. Based on Chinese expert consensus on the treatment of lumbar degenerative disease by trans-pedicle dynamic rod fixation, the rate of screw loosening can be reduced by preserving the integrity of the bony structure and ligaments of the posterior column during decompression; thicker and longer screws are preferred, and repeated adjustment of depth and direction need to be avoided when placing screws [49].

The disadvantages of DS should be highlighted. DS is designed to preserve lumbar vertebral mobility and reduce the load on the intervertebral disc; if these two points cannot be achieved, the use of this technique has no advantage [49]. The Dynesys device is subjected to continuous stress during weight-bearing of the spine. Thus, fixation failure may occur in the cases of severe osteoporosis and severe decreases of lumbar stabilization. Besides, DS cannot effectively stabilize the lumbar spine when used for isthmic spondylolisthesis with a high risk of fixation failure [50]. Moreover, for patients with severe stenosis in intervertebral space and small range of motion before surgery, the range of lumbar motion is limited after surgery, thus rendering the use of DS unsuitable [51].

This meta-analysis has several limitations. First, only one RCT along with 16 comparative cohort studies was included, resulting in less powerful results compared with that obtained purely from RCTs. Second, the definitions of ASDed and ASDis in previous studies are inconsistent and ambiguous. No consensus criterion has been established to define ASDed and ASDis, leading to imprecise outcome measures. Third, the number of the included studies was limited in terms of the ROM of LL, disc heigh at proximal adjacent segments, and ASDis. Furthermore, the fusion method is likely to encounter screw loosening initially, while the dynamic stabilization is likely to fail in the latter part. This flaw is expected in studies that evaluate early outcomes. Thus, future work should employ more RCTs of high quality and patients with follow-up more than 10 years from different cultural contexts.

## Conclusion

DS showed equivalent outcomes in terms of ODI, screw loosing, screw breakage, and ASDis compared with fusion method. Moreover, DS had better clinical measurements in terms of VAS scores for back and leg pain than fusion instrument. DS showed comparable clinical outcomes and provided benefits in preserving the motion at the stabilized segments, thus limiting the hypermobility at the adjacent segments and preventing ASDeg compared with the fusion method in degenerative disease with or without grade I spondylolisthesis.

#### Abbreviations

DS	Dynesys stabilization
ROM	Range of motion
ASDeg	Adjacent segment degeneration
ASDis	Adjacent segment disease
ASP	Adjacent segment pathology
PET	Polyethylene-terephtalate
PCU	Polycarbonate-urethane
PRISMA	The Preferred Reporting Items for Systematic Reviews and
	Meta-analyses
VAS	Visual analogue scale
ODI	Oswestry disability index
RCTs	Randomized controlled trials
NOS	Newcastle–Ottawa Scale
RR	Risk ratio
MD	Mean difference
CI	Confidence interval

## Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12893-023-01943-6.

Additional file 1	. Table :	51. Search	n strategy f	or each c	latabase.
-------------------	-----------	------------	--------------	-----------	-----------

Additional file 2. Table S2. Risk of bias assessment of the RCT study.

Additional file 3. Table S3. Risk of bias assessment of the cohort studies.

Additional file 4. Fig. S1. Forest plots of Dynesys stabilization versus instrumented fusion: (A) disc height at the intervertebral segment; (B) disc height at the proximal adjacent segment.

#### Acknowledgements

Not applicable.

#### Author contributions

L-PZ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing-original draft, Writing-editing. R-JZ: Conceptualization, Formal analysis, Investigation, Validation, Visualization, Writing-review. J-QW: Formal analysis, Investigation, Validation, Visualization, Writing-review. H-QZ: Formal analysis, Investigation, Methodology, Visualization, Writing-editing. JS: Formal analysis, Software, Validation, Visualization, Investigation, Investigation, Software, YG: Data curation, Writing-editing. C-YJ: Software, Writing-editing. J-YD: Data curation, Writing-editing. LZ: Software, Writing-editing. C-LS: Conceptualization, Project administration, Investigation, Methodology, Supervision, Writing-review. All authors read and approved the final manuscript.

#### Funding

Not applicable.

#### Availability of data and materials

All data generated or analyzed during this study are included in this published article and its Additional information files.

## Declarations

#### Ethics approval and consent to participate

This trial is a meta-analysis, which we collected data from other included studies. Ethics approval and consent to participate is not applicable.

## Consent for publication

Not applicable.

#### **Competing interests**

All authors confirmed that there is no conflict of interest regarding the submitted manuscript.

## Author details

<sup>1</sup>Department of Orthopedics and Spine Surgery, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei 230022, Anhui, China. <sup>2</sup>Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China, 107 Huanhudong Road, Hefei 230031, Anhui, China. <sup>3</sup>Outpatient Department, The 55th Retired Cadres of the Beijing Garrison of PLA, 4 Wanshou Road, Beijing 100036, China.

## Received: 15 December 2022 Accepted: 21 February 2023 Published online: 28 February 2023

#### References

- Yavin D, Casha S, Wiebe S, Feasby TE, Clark C, Isaacs A, Holroyd-Leduc J, Hurlbert RJ, Quan H, Nataraj A, et al. Lumbar fusion for degenerative disease: a systematic review and meta-analysis. Neurosurgery. 2017;80(5):701–15.
- 2. Lee JC, Choi S-W. Adjacent segment pathology after lumbar spinal fusion. Asian Spine J. 2015;9(5):807–17.
- Fei H, Xu J, Wang S, Xie Y, Ji F, Xu Y. Comparison between posterior dynamic stabilization and posterior lumbar interbody fusion in the treatment of degenerative disc disease: a prospective cohort study. J Orthop Surg Res. 2015;10:87.
- Wang Q, Liu J, Shi Y, Chen Y, Yu H, Ma J, Ren W, Yang H, Wang H, Xiang L. Short-term effects of a dynamic neutralization system (Dynesys) for multi-segmental lumbar disc herniation. Eur Spine J. 2016;25(5):1409–16.
- Zhang Y, Zhang ZC, Li F, Sun TS, Shan JL, Guan K, Zhao GM, Zhang LZ. Long-term outcome of dynesys dynamic stabilization for lumbar spinal stenosis. Chin Med J (Engl). 2018;131(21):2537–43.
- Zhang C, Berven SH, Fortin M, Weber MH. Adjacent segment degeneration versus disease after lumbar spine fusion for degenerative pathology. Clin Spine Surg. 2016;29(1):21–9.
- Hu A, Sun C, Liang Y, Wang H, Li X, Dong J. Multi-segmental lumbar spinal stenosis treated with Dynesys stabilization versus lumbar fusion in elderly patients: a retrospective study with a minimum of 5 years' follow-up. Arch Orthop Trauma Surg. 2019;139(10):1361–8.
- Hashimoto K, Aizawa T, Kanno H, Itoi E. Adjacent segment degeneration after fusion spinal surgery-a systematic review. Int Orthop. 2019;43(4):987–93.
- Huang Y-J, Zhao S-J, Zhang Q, Nong L-M, Xu N-W. Comparison of lumbar pedicular dynamic stabilisation systems versus fusion for the treatment of lumbar degenerative disc disease: a meta-analysis. Acta Orthop Belg. 2017;83(1):180–93.
- Lee SE, Jahng T-A, Kim H-J. Clinical experiences of non-fusion dynamic stabilization surgery for adjacent segmental pathology after lumbar fusion. Int J Spine Surg. 2016;10:8.

- Donnally CJ, Patel PD, Canseco JA, Divi SN, Goz V, Sherman MB, Shenoy K, Markowitz M, Rihn JA, Vaccaro AR. Current incidence of adjacent segment pathology following lumbar fusion versus motion-preserving procedures: a systematic review and meta-analysis of recent projections. Spine J. 2020;20(10):1554–65.
- Fayyazi AH, Ordway NR, Park S-A, Fredrickson BE, Yonemura K, Yuan HA. Radiostereometric analysis of postoperative motion after application of Dynesys dynamic posterior stabilization system for treatment of degenerative spondylolisthesis. J Spinal Disord Tech. 2010;23(4):236–41.
- Akyoldas G, Cevik OM, Suzer T, Sasani M, Oktenoglu T, Ozer AF. Dynamic stabilization of the lumbar spine using the dynesys system. Turk Neurosurg. 2020;30(2):190–3.
- Jung J-M, Hyun S-J, Kim K-J, Jahng T-A. Dynamic stabilization surgery in patients with spinal stenosis: Long-term outcomes and the future. Spine. 2021;46(16):E893–900.
- Wu H, Pang Q, Jiang G. Medium-term effects of Dynesys dynamic stabilization versus posterior lumbar interbody fusion for treatment of multisegmental lumbar degenerative disease. J Int Med Res. 2017;45(5):1562–73.
- He J, Li J, Luo C, Sun Y, Nong L, Xie H. Impact of the Dynesys dynamic stabilization system on the fixation-adjacent intervertebral discs. Int J Clin Exp Med. 2016;9(7):14698–703.
- Yang M, Li C, Chen Z, Bai Y, Li M. Short term outcome of posterior dynamic stabilization system in degenerative lumbar diseases. Indian J Orthop. 2014;48(6):574–81.
- Zhao C, Liu L, Luo L, Li P, Wang Y, Liang L, Wen X, Jiang D, Zhou Q. Effect of discectomy on Dynesys dynamic fixation in the treatment of lumbar degenerative diseases. Pain Res Manag. 2021;2021:3043645.
- Luo L, Zhao C, Li P, Liu L, Zhou Q, Luo F, Liang L. Posterior dynamic stabilization with limited rediscectomy for recurrent lumbar disc herniation. Pain Res Manag. 2021;2021:1288246.
- Zhang C, Wang L, Hou T, Luo L, Zhao C, Gan Y, Zhou Q, Li P. The influence of L4–S1 Dynesys<sup>®</sup> dynamic stabilization versus fusion on lumbar motion and its relationship with lumbar degeneration: a retrospective study. J Orthop Surg Res. 2017;12(1):99.
- Yu S-W, Yang S-C, Ma C-H, Wu C-H, Yen C-Y, Tu Y-K. Comparison of Dynesys posterior stabilization and posterior lumbar interbody fusion for spinal stenosis L4L5. Acta Orthop Belg. 2012;78(2):230–9.
- Kuo C-H, Huang W-C, Wu J-C, Tu T-H, Fay L-Y, Wu C-L, Cheng H. Radiological adjacent-segment degeneration in L4–5 spondylolisthesis: comparison between dynamic stabilization and minimally invasive transforaminal lumbar interbody fusion. J Neurosurg Spine. 2018;29(3):250–8.
- St-Pierre GH, Jack A, Siddiqui MMA, Henderson RL, Nataraj A. Nonfusion does not prevent adjacent segment disease: Dynesys long-term outcomes with minimum five-year follow-up. Spine. 2016;41(3):265–73.
- Zhang Y, Shan J-L, Liu X-M, Li F, Guan K, Sun T-S. Comparison of the dynesys dynamic stabilization system and posterior lumbar interbody fusion for lumbar degenerative disease. PLoS ONE. 2016;11(1):E0148071.
- Silvestre MD, Lolli F, Bakaloudis G. Degenerative lumbar scoliosis in elderly patients: dynamic stabilization without fusion versus posterior instrumented fusion. Spine J. 2014;14(1):1–10.
- Haddad B, Makki D, Konan S, Park D, Khan W, Okafor B. Dynesys dynamic stabilization: less good outcome than lumbar fusion at 4-year follow-up. Acta Orthop Belg. 2013;79(1):97–103.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):E1000100.
- Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. http://www. cochrane-handbook.org. Accessed March 20, 2012.
- Wells GA, Shea B, O'Connell D, Robertson J, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 2011. http://www.ohri.ca/progr ams/clinicalepidemiology/oxford.asp Accessed April 15, 2012.
- Liu K, Sun W, Lu Q, Chen J, Tang J. A cost-utility analysis of Dynesys dynamic stabilization versus instrumented fusion for the treatment of degenerative lumbar spine diseases. J Orthop Sci. 2017;22(6):982–7.
- 31. Luo L, Liu L, Li P, Zhao C, Liang L, Luo F, Zhou Q, Chen Y, Fang L. Comparison between dynamic stabilization and instrumented fusion in the

treatment of spinal stenosis with degenerative lumbar scoliosis. Pain Res Manag. 2022;2022:9367106.

- Zheng C, Liu J, Du J, Ma W, Chen Y, Wu J. Application of Dynesys dynamic stabilization with microendoscopic discectomy for the degenerative lumbar spinal stenosis in the elder. Chin J Orthop. 2021;41(17):1247–56.
- Zhang K, Luo K, Cai K, Lu B, Lu J, Jiang G, Wu H. Medium and long-term comparisons of Dynesys stabilization and posterior lumbar interbody fusion for two-level lum- bar degenerative diseases. Chin J Orthop. 2021;41(17):1180–7.
- Ren D-W, Li Q, Jia T, He Y. Comparison of the Dynesys dynamicinternal system and transforminal lumbar interbody fusion for degenerative L5/S1 disc herniation. Orthopaedics. 2018;9(6):445–50.
- Bredin S, Demay O, Mensa C, Madi K, Ohl X. Posterolateral fusion versus Dynesys dynamic stabilization: retrospective study at a minimum 5.5 years' follow-up. Orthop Traumatol Surg Res. 2017;103(8):1241–4.
- Veresciagina K, Mehrkens A, Schären S, Jeanneret B. Minimum tenyear follow-up of spinal stenosis with degenerative spondylolisthesis treated with decompression and dynamic stabilization. J Spine Surg. 2018;4(1):93–101.
- Hoppe S, Schwarzenbach O, Aghayev E, Bonel H, Berlemann U. Longterm outcome after monosegmental L4/5 stabilization for degenerative spondylolisthesis with the Dynesys device. Clin Spine Surg. 2012;29(2):72–7.
- Schaeren S, Broger I, Jeanneret B. Minimum four-year follow-up of spinal stenosis with degenerative spondylolisthesis treated with decompression and dynamic stabilization. Spine. 2008;33(18):E636–42.
- Más Y, Gracia L, Ibarz E, Gabarre S, Peña D, Herrera A. Finite element simulation and clinical follow-up of lumbar spine biomechanics with dynamic fixations. PLoS ONE. 2017;12(11):E0188328.
- Kumar A, Beastall J, Hughes J, Karadimas EJ, Nicol M, Smith F, Wardlaw D. Disc changes in the bridged and adjacent segments after Dynesys dynamic stabilization system after two years. Spine. 2008;33(26):2909–14.
- 41. Klöckner C. Long-term results of the Dynesys implant. Orthopade. 2010;39(6):559–64.
- Hoff E, Strube P, Gross C, Putzier M. Sequestrectomy with additional transpedicular dynamic stabilization for the treatment of lumbar disc herniation: no clinical benefit after 10 years follow-up. Spine. 2013;38(11):887–95.
- Shih S-L, Liu C-L, Huang L-Y, Huang C-H, Chen C-S. Effects of cord pretension and stiffness of the dynesys system spacer on the biomechanics of spinal decompression- a finite element study. BMC Musculoskelet Disord. 2013;14:191.
- Mesbah M, Barkaoui A. Biomechanical investigation of the effect of pedicle-based hybrid stabilization constructs: a finite element study. Proc Inst Mech Eng H. 2020;234(9):931–41.
- 45. Lee C-H, Jahng T-A, Hyun S-J, Kim CH, Park S-B, Kim K-J, Chung CK, Kim H-J, Lee S-E. Dynamic stabilization using the Dynesys system versus posterior lumbar interbody fusion for the treatment of degenerative lumbar spinal disease: a clinical and radiological outcomes-based meta-analysis. Neurosurg Focus. 2016;40(1):E7.
- Jahng T-A, Kim YE, Moon KY. Comparison of the biomechanical effect of pedicle-based dynamic stabilization: a study using finite element analysis. Spine J. 2013;13(1):85–94.
- Ko CC, Tsai HW, Huang WC, Wu JC, Chen YC, Shih YH, Chen HC, Wu CL, Cheng H. Screw loosening in the Dynesys stabilization system: radiographic evidence and effect on outcomes. Neurosurg Focus. 2010;28(6):E10.
- Hu A, Chen F, Jiang L, Jiang Y, Lin H, Li X, Zhou X, Dong J. Mid- and longterm outcomes of hybrid surgery combined Dynesys fusion and nonfusion stabilization in the treatment of degenerative lumbar diseases. Chin J Orthop. 2021;41(17):1237–46.
- The Lumbar Research Group of Spinal Cord Committee of Chinese Association of Rehabilitation Medicine. Expert consensus on the treatment of lumbar degenerative disease by transpedicle dynamic rod fixation. Chin J Orthop 2020; 40(24):1639–1645.
- Guo J, Hou S, Shi Y, Li L, Wang H. Early clinical effects of Dynesys dynamic internal fixation system for mild lumbar degenerative spondylolisthesis. Chin J Bone Joint. 2013;2(6):318–21.
- 51. Schwaiger BJ, Behr M, Gersing AS, Meyer B, Zimmer C, Kirschke JS, Ryang YM, Ringel F. Computed tomography findings associated with clinical

outcome after dynamic posterior stabilization of the lumbar spine. World Neurosurg. 2016;93:306–14.

## **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

